- Home
- LFCR vs ABOS Comparison
LFCR vs ABOS Comparison
Compare LFCR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFCR | ABOS |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.9M | 197.9M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LFCR | ABOS |
|---|---|---|
| Price | $4.39 | $2.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | 145.6K | ★ 361.4K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $557,559,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $3.63 | $1.19 |
| 52 Week High | $8.98 | $3.60 |
Technical Indicators
Market Signals| Indicator | LFCR | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 33.10 | 42.97 |
| Support Level | $4.22 | $2.13 |
| Resistance Level | $5.34 | $2.45 |
| Average True Range (ATR) | 0.26 | 0.15 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 3.30 | 16.67 |
Price Performance
Historical ComparisonAbout LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.